Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Morale Improvement Will Be A Priority, Von Eschenbach Testifies

This article was originally published in The Gray Sheet

Executive Summary

Acting FDA Commissioner Andrew von Eschenbach stressed his commitment to improving agency morale during his confirmation hearing

You may also be interested in...



Von Eschenbach Nomination Still Stalled After Some Movement On Plan B

Senators Hilary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) will maintain their hold on Andrew von Eschenbach's nomination to head FDA, despite what von Eschenbach calls an "important decision" regarding Barr Laboratories' application to offer its Plan B emergency contraceptive over the counter (OTC)

FDA Scientists Fear Retaliation For Conveying Health Risks, Survey Finds

FDA scientists fear retaliation for expressing health concerns to the public, according to results of a Union of Concerned Scientists survey released July 20

Increasing Number Of Appeals Add To Unresolved Issues For Ombudsman

CDRH's ombudsman says more manufacturer appeals of decisions made by the device center's evaluation office are causing longer resolution times for many complaints and disputes filed with the center

Related Content

UsernamePublicRestriction

Register

MT023847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel